Last reviewed · How we verify
MVC-COV1901
MVC-COV1901 is a protein subunit vaccine that stimulates immune responses against SARS-CoV-2 by presenting viral spike protein antigens to the immune system.
MVC-COV1901 is a protein subunit vaccine that stimulates immune responses against SARS-CoV-2 by presenting viral spike protein antigens to the immune system. Used for COVID-19 prevention in adults.
At a glance
| Generic name | MVC-COV1901 |
|---|---|
| Sponsor | Medigen Vaccine Biologics Corp. |
| Drug class | Protein subunit vaccine |
| Target | SARS-CoV-2 spike protein |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains recombinant SARS-CoV-2 spike protein produced in insect cells, formulated with an adjuvant to enhance immunogenicity. It is designed to elicit both humoral (antibody) and cellular (T-cell) immune responses against the spike protein, enabling the body to recognize and neutralize the virus upon exposure.
Approved indications
- COVID-19 prevention in adults
Common side effects
- Injection site pain or swelling
- Fatigue
- Headache
- Myalgia
- Fever
Key clinical trials
- Immunogenicity of COVID-19 Vaccine on Heterologous Schedule (PHASE2)
- A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults (PHASE4)
- A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above (PHASE3)
- A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222 (PHASE3)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19 (PHASE1)
- A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19 (PHASE2)
- A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults (PHASE3)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MVC-COV1901 CI brief — competitive landscape report
- MVC-COV1901 updates RSS · CI watch RSS
- Medigen Vaccine Biologics Corp. portfolio CI